Neuromyelitis optica in patients with increased interferon alpha concentrations

Scottish NMOSD study group

doi:10.1016/S1474-4422(19)30445-4

Neuromyelitis optica in patients with increased interferon alpha concentrations

Scottish NMOSD study group

Psychology

Research output: Contribution to journal › Letter › peer-review

13 Scopus citations

Original language	English (US)
Pages (from-to)	31-33
Number of pages	3
Journal	The Lancet Neurology
Volume	19
Issue number	1
DOIs	https://doi.org/10.1016/S1474-4422(19)30445-4
State	Published - Jan 2020

ASJC Scopus subject areas

Clinical Neurology

Access to Document

10.1016/S1474-4422(19)30445-4

Cite this

@article{3eecc8d29220470aa02dae5c92bf0d33,

title = "Neuromyelitis optica in patients with increased interferon alpha concentrations",

author = "{Scottish NMOSD study group} and Jac Williams and Sarah McGlasson and Sarosh Irani and Darragh Duffy and Yanick Crow and David Hunt and Murray Katy and Wilson Robert and {Andrew P}, Jackson and Jury Alexa and Rodero Mathieu and Bondet Vincent and Jacob Anu and Hamid Shahd and Cordeiro Nuno and Dolezal Ondrej and Statham Patrick and Wiseman Stewart and Wardlaw Joanna and Hertel Christina and Hayday Adrian",

note = "Funding Information: DH is supported by the Wellcome Trust (215621/Z/19/Z) and the Medical Research Foundation. YC is supported by an European Research Council advanced grant (786142-E-T1IFNs). YC and DH are supported by Connect Immune research (Multiple Sclerosis Society, Juvenile Diabetes Research Foundation, Versus Arthritis). AJ is supported by the UK Medical Research Council. SRI is supported by the Wellcome Trust (104079/Z/14/Z), the British Medical Association's Vera Down (2013) and Margaret Temple (2017) grants, and Epilepsy Research UK (P1201). The research was funded by the National Institute for Health Research (NIHR) Oxford Biomedical Research Centre. The views expressed are those of the authors and not necessarily those of the UK National Health Service (NHS), the NIHR, or the UK Department of Health. We thank the Uppsala Monitoring Centre (Uppsala, Sweden) and the UK Medicines and Healthcare products Regulatory Agency for providing spontaneous reporting data. We thank our patients for willingness and consent to report these cases. Patients 1, 3, and 4 were enrolled in clinical studies approved by: Leeds (East) Research Ethics Committee (10/H1307/132; patient 3) and South-East Scotland Research Ethics Committee 01 (14/SS/0003; patients 1 and 4). The Scottish Neuromyelitis Optica Spectrum Disorder Clinic is part of the NHS NMO UK specialised service.",

year = "2020",

month = jan,

doi = "10.1016/S1474-4422(19)30445-4",

language = "English (US)",

volume = "19",

pages = "31--33",

journal = "The Lancet Neurology",

issn = "1474-4422",

publisher = "Elsevier Ltd",

number = "1",

}

TY - JOUR

T1 - Neuromyelitis optica in patients with increased interferon alpha concentrations

AU - Scottish NMOSD study group

AU - Williams, Jac

AU - McGlasson, Sarah

AU - Irani, Sarosh

AU - Duffy, Darragh

AU - Crow, Yanick

AU - Hunt, David

AU - Katy, Murray

AU - Robert, Wilson

AU - Andrew P, Jackson

AU - Alexa, Jury

AU - Mathieu, Rodero

AU - Vincent, Bondet

AU - Anu, Jacob

AU - Shahd, Hamid

AU - Nuno, Cordeiro

AU - Ondrej, Dolezal

AU - Patrick, Statham

AU - Stewart, Wiseman

AU - Joanna, Wardlaw

AU - Christina, Hertel

AU - Adrian, Hayday

N1 - Funding Information: DH is supported by the Wellcome Trust (215621/Z/19/Z) and the Medical Research Foundation. YC is supported by an European Research Council advanced grant (786142-E-T1IFNs). YC and DH are supported by Connect Immune research (Multiple Sclerosis Society, Juvenile Diabetes Research Foundation, Versus Arthritis). AJ is supported by the UK Medical Research Council. SRI is supported by the Wellcome Trust (104079/Z/14/Z), the British Medical Association's Vera Down (2013) and Margaret Temple (2017) grants, and Epilepsy Research UK (P1201). The research was funded by the National Institute for Health Research (NIHR) Oxford Biomedical Research Centre. The views expressed are those of the authors and not necessarily those of the UK National Health Service (NHS), the NIHR, or the UK Department of Health. We thank the Uppsala Monitoring Centre (Uppsala, Sweden) and the UK Medicines and Healthcare products Regulatory Agency for providing spontaneous reporting data. We thank our patients for willingness and consent to report these cases. Patients 1, 3, and 4 were enrolled in clinical studies approved by: Leeds (East) Research Ethics Committee (10/H1307/132; patient 3) and South-East Scotland Research Ethics Committee 01 (14/SS/0003; patients 1 and 4). The Scottish Neuromyelitis Optica Spectrum Disorder Clinic is part of the NHS NMO UK specialised service.

PY - 2020/1

Y1 - 2020/1

UR - http://www.scopus.com/inward/record.url?scp=85076246216&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85076246216&partnerID=8YFLogxK

U2 - 10.1016/S1474-4422(19)30445-4

DO - 10.1016/S1474-4422(19)30445-4

M3 - Letter

C2 - 31839246

AN - SCOPUS:85076246216

SN - 1474-4422

VL - 19

SP - 31

EP - 33

JO - The Lancet Neurology

JF - The Lancet Neurology

IS - 1

ER -

Neuromyelitis optica in patients with increased interferon alpha concentrations

ASJC Scopus subject areas

Access to Document

Other files and links

Cite this